Bristol Myers Squibb

BMY · Health Care · Market cap $131B

Q2 FY26 Apr 1 – Jun 30, 2026 reported Jul 30, 2026

Revenue$13B +6% year over year

Gross profit$9.2B

Operating profit$-0.8B

Net profit$3.3B 26% margin

Numbers and detail

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
Item	Value	Share of revenue	Year over year
Revenue	13	100%	+6%
Growth Portfolio	7.6	58%
Eliquis	4.5	35%
Revlimid	0.4	3%	−49%
Pomalyst/Imnovid	0.2	2%	−71%
Other Legacy products	0.2	2%	−24%
Sprycel	0.1	1%	−27%
Abraxane	0.1	1%	−48%
Cost of revenue	−3.7	28%
Gross profit	9.2	71% margin	−1pp
Research & development	−3	23%	+2pp
SG&A	−1.8	14%	+0pp
Other	−5.3	41%	+0pp
Operating profit	-0.8	-6% margin	+0pp
Tax	−0.8
Net profit	3.3	26%	+15pp

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	11.5	100%	+3%
Growth Portfolio	6.2	54%	+12%
Eliquis	4.1	36%	+16%
Pomalyst/Imnovid	0.5	4%	−22%
Revlimid	0.3	3%	−63%
Other Legacy products (b)	0.2	2%	−22%
Sprycel	0.1	1%	−58%
Abraxane	0.1	1%	−52%
Cost of revenue	−3.4	30%
Gross profit	8.1	70% margin	−3pp
Research & development	−2.6	23%	+3pp
SG&A	−1.6	14%	+0pp
Other	−4.3	38%	+0pp
Operating profit	-0.5	-5% margin	+0pp
Tax	−0.6
Net profit	2.7	23%	+1pp

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	12.2	100%	+3%
International	3.6	30%
Other	2.6	21%
Opdivo	2.5	20%
Orencia	1	8%
Yervoy	0.7	6%
Pomalyst/Imnovid	0.7	6%	−25%
Reblozyl	0.6	5%
Revlimid	0.6	5%	−59%
Cost of revenue	−3.4	28%
Gross profit	8.8	72% margin	−3pp
Research & development	−2.5	21%	+1pp
SG&A	−1.8	15%	−2pp
Other	−5.5	45%	+0pp
Operating profit	-1	-8% margin	+0pp
Tax	−0.9
Net profit	2.2	18%	+8pp

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	12.3	100%	+1%
International	3.5	28%
Opdivo	2.6	21%
Other	2.4	20%
Orencia	1	8%
Revlimid	0.8	7%	−38%
Yervoy	0.7	6%
Pomalyst/Imnovid	0.7	6%	−26%
Reblozyl	0.6	5%
Cost of revenue	−3.4	28%
Gross profit	8.9	73% margin	−1pp
Research & development	−2.6	21%	−3pp
SG&A	−1.7	14%	−2pp
Other	−5.1	41%	+0pp
Operating profit	-0.5	-4% margin	+0pp
Tax	−0.4
Net profit	1.3	11%	−3pp

All figures in billions of U.S. dollars, for Q1 FY25 (period ends Mar 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	11.2	100%	−6%
Eliquis	3.6	32%
Opdivo	2.3	21%
Other	1.8	16%
Revlimid	0.9	8%
Orencia	0.8	7%
Pomalyst/Imnovid	0.7	6%
Yervoy	0.6	5%
Reblozyl	0.5	4%
Cost of revenue	−3	27%
Gross profit	8.2	73% margin	−2pp
Research & development	−2.3	20%	−3pp
SG&A	−1.6	14%	−6pp
Other	−4.8	43%	+0pp
Operating profit	-0.5	-5% margin	+0pp
Tax	−0.5
Net profit	2.5	22%	+122pp

Quarter by quarter

Pick a quarter and the diagram above changes. Bars compare revenue across the quarters we hold.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q2 FY26	Apr 1 – Jun 30, 2026	Jul 30, 2026	$13B	+6%	-6%	$3.3B	26%
Q1 FY26	Mar 31, 2026	Apr 30, 2026	$11.5B	+3%	-4%	$2.7B	23%
Q3 FY25	Jul 1 – Sep 30, 2025	Oct 30, 2025	$12.2B	+3%	-8%	$2.2B	18%
Q2 FY25	Apr 1 – Jun 30, 2025	Jul 31, 2025	$12.3B	+1%	-4%	$1.3B	11%
Q1 FY25	Jan 1 – Mar 31, 2025	Apr 24, 2025	$11.2B	−6%	-4%	$2.5B	22%